Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

BioNTech sees differentiation in OncoC4’s CTLA-4, commits $200M up front

German biotech to explore combinations with molecule engineered to affect tumor microenvironment without triggering unwanted autoimmune effects

March 20, 2023 7:20 PM UTC

An early clinical readout for OncoC4’s anti-CTLA-4 antibody has helped drive a deal that gives BioNTech rights to the program for $200 million up front.

BioNTech SE (NASDAQ:BNTX) will receive exclusive, worldwide rights to ONC-392, which is in Phase I/II testing as monotherapy and in combination with Keytruda pembrolizumab to treat solid tumors, including melanoma and lung and ovarian cancers. The deal includes milestones and royalties of undisclosed size due to OncoC4 Inc...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article